Close Menu

NEW YORK (360Dx) – Interpace Diagnostics reported after the close of the market on Monday that its first quarter revenues rose 25 percent year over year.

For the three months ended March 31, the firm reported revenues of $6.0 million, up from $4.8 million in the year-ago quarter, but missed the consensus Wall Street estimate of $6.3 million.

Interpace President and CEO Jack Stover said in a statement that the firm had a strong start to the year, driven in part by increasing sales volumes for its gastrointestinal PancraGen business and endocrine ThyGeNext/ThyraMir business.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.